We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Illumina Announces MiSeq™ Personal Sequencing System
Product News

Illumina Announces MiSeq™ Personal Sequencing System

Illumina Announces MiSeq™ Personal Sequencing System
Product News

Illumina Announces MiSeq™ Personal Sequencing System


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Illumina Announces MiSeq™ Personal Sequencing System"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Illumina, Inc. has announced MiSeq™, a low-cost personal sequencing system that provides individual researchers a platform with rapid turnaround time, unmatched accuracy, and radically improved ease of use. Leveraging the company's TruSeq™ sequencing chemistry, the system's revolutionary workflow offers the flexibility to go from purified DNA to analyzed data in as few as eight hours, or to generate in excess of 1 gigabase per run in slightly over a day.

Expected to be priced under $125,000 with individual run prices ranging from $400-$750, MiSeq will be the most affordable next-generation sequencing (NGS) platform available.

"MiSeq takes advantage of recent advances in our sequencing chemistry, including significantly faster cycle times and simplified sample preparation, to deliver next-generation sequencing to individual researchers, especially those who currently use capillary electrophoresis (CE) sequencers," said Jay Flatley, President and CEO of Illumina.

Flatley continued, "Users will also benefit greatly from MiSeq's compact footprint of approximately 2 feet square, intuitive user interface, simple workflow, and low capital and run price. The platform will enable applications such as amplicon sequencing, clone checking, small genome sequencing, ChIP-Seq, and RNA-Seq, all with a single, integrated instrument and at a fraction of current costs and time."

Using Illumina's proven TruSeq chemistry, MiSeq provides users the flexibility to optimize run conditions to suit their particular applications. Like all other Illumina sequencing platforms, MiSeq performs both single and paired-end runs with read lengths of up to 2 x 150 base pairs. The ability to support paired-end reads is critical for a broad range of applications including amplicon sequencing, sequencing of complex genome regions, and efficient mapping.

The platform also leverages a new proprietary protocol for efficient and cost-effective targeting of 10s to 100s of amplicons, allowing CE users to complete their projects in a fraction of the time at significant cost savings. To accommodate space limitations often encountered in smaller laboratories, cluster amplification has been integrated with the 2 feet square platform.

This eliminates the need for additional instruments, which are often necessary to operate other NGS platforms, especially those that rely on emulsion PCR (ePCR) for sample amplification.

Advertisement